Ernexa Therapeutics (ERNAW) Receivables - Other (2018 - 2026)

Ernexa Therapeutics (ERNAW) has 9 years of Receivables - Other data on file, last reported at $95000.0 in Q1 2026.

• Quarterly Receivables - Other rose 133.81% year-over-year to $95000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95000.0 (up 107.0% YoY) and the FY2025 annual result came in at $750000.0, up 71.62% from the prior year.
• Receivables - Other climbed to $95000.0 in Q1 2026, from -$58000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.8 million in Q3 2023 to a low of -$1.4 million in Q4 2023.
• A 5-year average of $330235.3 and a median of $228000.0 in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other jumped 69500.0% — and 2023, when it sank 5508.0%.
• Tracing ERNAW's Receivables - Other over 5 years: stood at $25000.0 in 2022, then slumped by 5508.0% to -$1.4 million in 2023, then soared by 118.49% to $250000.0 in 2024, then plunged by 123.2% to -$58000.0 in 2025, then surged by 263.79% to $95000.0 in 2026.
• The last three Receivables - Other figures came in at $95000.0 (Q1 2026), -$58000.0 (Q4 2025), and $153000.0 (Q3 2025), per Business Quant data.